We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

LumiraDx Point of Care COVID-19 Antigen Test Detects All Major Global SARS-CoV-2 Variants

By LabMedica International staff writers
Posted on 28 Jun 2021
LumiraDx (London, UK) has confirmed that its LumiraDx SARS-CoV-2 Ag Test detects major global SARS-CoV-2 variants, including the Alpha, Beta, Gamma, Delta and Epsilon variants.

SARS-CoV-2, like other viruses, is constantly mutating, and becoming more diverse with new variants of the virus occurring over time. While some new variants may emerge and disappear, or be clinically inconsequential, others emerge and dominate and have been detected globally during this pandemic. LumiraDx is actively monitoring how its SARS-CoV-2 Antigen test performs against new variants of the SARS-CoV-2 virus. The company's in-house evaluation is carried out using in silico analysis and direct testing with either recombinant nucleocapsid protein or viral isolates.

Image: LumiraDx SARS-CoV-2 Ag Test (Photo courtesy of LumiraDx)
Image: LumiraDx SARS-CoV-2 Ag Test (Photo courtesy of LumiraDx)

The LumiraDx SARS-CoV-2 Antigen test is well positioned to detect these existing and new variants. Unlike PCR, the LumiraDx SARS-CoV-2 Ag Test uses antibodies, not nucleic acid based-primers, to capture SARS-CoV-2 nucleocapsid antigen, not the spike protein. Antibodies typically recognize 8-15 amino acid target sequences which are equivalent to 24-45 nucleotide sequences. Thus, single nucleic acid point mutations are not likely to affect the performance of the LumiraDx SARS-CoV-2 Ag Test. Furthermore, mutations outside of the nucleocapsid viral coding region (ex Spike protein) are also unlikely to affect the assay performance.

"Since the COVID-19 virus emerged early last year, we have learned an extraordinary amount about how this virus spreads and importantly, how it can mutate," said Nigel Lindner, PhD, LumiraDx's Chief Innovation Officer. "We know that testing is a critical component in the monitoring and controlling of the spread of the virus. This becomes even more important with the emergence of new, and unfamiliar variants. We are committed not only to ensuring we are following all guidelines to monitor for these variants of concern, but also to sharing this data and our monitoring program process with our customers."

Related Links:
LumiraDx


Gold Member
Turnkey Packaging Solution
HLX
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Liquid Based Cytology Production Machine
LBP-4032
New
Chemistry Analyzer
MS100

Latest COVID-19 News

New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases

Long COVID Etiologies Found in Acute Infection Blood Samples

Novel Device Detects COVID-19 Antibodies in Five Minutes